Audiomedica.com
PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:00:06
- Mas informaciones
Informações:
Sinopsis
MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among patients with metastatic triple-negative breast cancer in the randomized phase three IMpassion130 trial reported at the 2018 …Peter Schmid AJO Atezolizumab Extends Lif e in Triple Negative Breast Cancer
